Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

Inclusion Criteria: * biopsy proven adenocarcinoma of the colon or rectum and synchronous or metachronous peritoneal carcinomatosis. * absence of systemic disease, with the exception of small, superficial liver metastases, requiring only minor surgery. * resectable disease at staging, during laparoscopic evaluation and during exploration for cytoreductive surgery and intraperitoneal chemotherapy. * complete macroscopic cytoreduction at the time of surgery (CC-0/1) * good general health status (Karnofsky index \> 70%) * expected life expectancy more than 6 months * no other malignancy than disease under study * serum creatinine \< 1.5 mg/dl or a calculated GFR ≥ 60 mL/min/1.73 m2 * serum total bilirubin \< 1.5 mg/dl * platelet count \> 100,000/ml * hemoglobin \> 9g/dl * neutrophil granulocytes \> 1,500/ml * International Normalized Ration (INR) 2 or \< 2 * Absence of alcohol and/or drug abuse * No inclusion in other clinical trials interfering with the study protocol * No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol * Absence of heart failure (NYHA 2 or \> 2) or significant coronary artery disease * No pregnancy or breast feeding * Adequate contraception in fertile patients Exclusion Criteria: * No written informed consent * Tumour in the presence of obstruction * Evidence of extra-abdominal disease or extensive liver metastasis * Peritoneal cancer index \> 25 * Active bacterial, viral or fungal infection * Active gastro-duodenal ulcer * Parenchymal liver disease (any stage cirrhosis) * Uncontrolled diabetes mellitus * Severe obstructive or restrictive respiratory insufficiency * Psychiatric pathology capable of affecting comprehension and judgment faculty * Known allergy to oxaliplatin.